Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
NEW YORK, October 28, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), Magellan Health Services Inc. (NASDAQ: MGLN), Foundation Medicine, Inc. (NASDAQ: FMI), and InterMune Inc. (NASDAQ: ITMN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alere Inc. Research Report
On October 23, 2013, Alere Inc. (Alere) announced an educational partnership with the Alliance for the Prudent Use of Antibiotics (APUA) to expand the impact of Alere's new Test Target Treat campaign website. According to Alere, APUA will provide non-commercial, expert educational material for the Company's antimicrobial stewardship initiative. Alere reported that the new website will broaden the distribution of APUA's standard non-commercial messages and will boost global awareness of antibiotic resistance and effective interventions. The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5da1_ALR]
Ironwood Pharmaceuticals, Inc. Research Report
On October 22, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) released Q3 2013 results. Ironwood registered revenues of $4.9 million in Q3 2013, down compared to revenues of $96.4 million in Q3 2012. The Company reported net loss of $61.8 million in Q3 2013, compared to net income of $47.6 million in Q3 2012. Ironwood's diluted loss per share was $0.51 in Q3 2013, compared to diluted EPS of $0.42 in Q3 2012. Peter Hecht, CEO of Ironwood, stated, "This quarter, we continued to make good progress across our key value drivers. LINZESS is performing well across the key leading indicators, reinforcing the significant opportunity we see ahead. Our scientists continue to advance the pharmacology of linaclotide and explore its utility more broadly while also progressing our broader pipeline, and our global partners are making important strides in bringing linaclotide to appropriate patients worldwide." The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/dbc4_IRWD]
Magellan Health Services Inc. Research Report
On October 1, 2013, Magellan Health Services Inc. (Magellan Health Services) announced that it has successfully completed its acquisition of Partners Rx, a privately held, full-service commercial pharmacy benefits management company (PBM) with a strong focus on health plans and self-funded employers. Barry M. Smith, CEO of Magellan, commented, "Our acquisition of Partners Rx will enhance our full-service PBM capabilities by adding scale, relationships and expertise." Smith added, "It complements our unique medical pharmacy and specialty pharmacy capabilities, and will enable us to expand our presence in the marketplace." Magellan Health Services reported that it paid $100 million from existing cash on hand. The Full Research Report on Magellan Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4b85_MGLN]
Foundation Medicine, Inc. Research Report
On October 20, 2013, Foundation Medicine, Inc. (Foundation Medicine) announced that results from a 24-month, multi-institution collaboration demonstrating the analytic validation of its cancer genomic profiling assay, FoundationOne, were published in the current online edition of Nature Biotechnology. According to Foundation Medicine, FoundationOne is a comprehensive, next-generation sequencing (NGS) based test used to characterize all classes of molecular alterations (base substitutions, short insertions and deletions (indels), copy number alterations and select rearrangements) across 287 cancer-related genes from routine formalin-fixed, paraffin-embedded (FFPE) clinical specimens. The Company reported that the publication also describes clinical application of this assay across 2,221 consecutive patient cases. The Full Research Report on Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d9a0_FMI]
InterMune Inc. Research Report
On October 23, 2013, InterMune Inc. (InterMune) announced that it will release its Q3 2013 results after the US markets close on Wednesday, October 30, 2013. InterMune reported that the Q3 2013 live conference call will be held on the same day at 4:30 p.m. ET. The Company stated that interested parties may access the live call and its replay through its website. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/dd8c_ITMN]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.